Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of increases in drug prices on oncology stakeholders.
Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of increases in drug prices on oncology stakeholders.
Trascript
What is the impact of novel therapies on oncology stakeholders?
The whole challenge with healthcare these days is the total cost of care, and these new cancer therapies have really changed the cost paradigm. So, going from drugs that were hundreds or thousands of dollars to drugs that are hundreds of thousands of dollars has an impact on employers, it’s likely to raise the total cost of care, certainly the patient out-of-pocket expense with high deductible plans can be a real factor. But, the biggest impact is really on hospitals and insurance providers because therapies that are administered in inpatient are often included within a DRG, and that cost obviously blows up what the traditional DRG is. For those that are outpatient, it’s an added cost to the insurers, and the ability to understand what those costs are in an appropriately priced product when they’re selling them, (ie passing them on to the ultimate payer). It’s a real revolution in the costs of understanding how to manage this kind of cost in the explosion of new therapies is a real challenge, and figuring that out is gonna be the next few year’s work.
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinerof cream.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More